$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000143853320000011 Filed on May 11, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$47.77M	$39.57M
YoY Change	20.72%	2.96%
Cost Of Revenue	$1.370M	$1.017M
YoY Change	34.71%	-36.95%
Gross Profit	$46.40M	$38.55M
YoY Change	20.35%	4.71%
Gross Profit Margin	97.13%	97.43%
Selling, General & Admin	$33.14M	$32.67M
YoY Change	1.44%	23.43%
% of Gross Profit	71.42%	84.74%
Research & Development	$30.25M	$33.44M
YoY Change	-9.55%	35.75%
% of Gross Profit	65.19%	86.75%
Depreciation & Amortization	$5.656M	$4.901M
YoY Change	15.41%	12.72%
% of Gross Profit	12.19%	12.71%
Operating Expenses	$62.84M	$77.80M
YoY Change	-19.23%	38.08%
Operating Profit	-$15.07M	-$38.23M
YoY Change	-60.59%	113.42%
Interest Expense	-$4.887M	-$4.865M
YoY Change	0.45%	321.21%
% of Operating Profit
Other Income/Expense, Net	-$3.101M	-$2.348M
YoY Change	32.07%	890.72%
Pretax Income	-$18.17M	-$40.58M
YoY Change	-55.22%	123.57%
Income Tax	-$19.00M	$401.0K
% Of Pretax Income
Net Earnings	$808.0K	-$40.98M
YoY Change	-101.97%	122.97%
Net Earnings / Revenue	1.69%	-103.56%
Basic Earnings Per Share	$0.02	-$0.99
Diluted Earnings Per Share	$0.02	-$0.99
COMMON SHARES
Basic Shares Outstanding	43.12M shares	41.41M shares
Diluted Shares Outstanding	43.59M shares	41.41M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$269.9M	$270.7M
YoY Change	-0.3%	2.52%
Cash & Equivalents	$67.02M	$69.84M
Short-Term Investments	$202.8M	$200.8M
Other Short-Term Assets	$5.300M	$9.600M
YoY Change	-44.79%	108.7%
Inventory	$6.593M	$5.571M
Prepaid Expenses
Receivables	$18.10M	$12.71M
Other Receivables	$20.20M	$0.00
Total Short-Term Assets	$406.6M	$475.5M
YoY Change	-14.49%	65.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.617M	$2.995M
YoY Change	-12.62%	-1.55%
Goodwill	$936.0K	$936.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments		$15.00M
YoY Change		0.0%
Other Assets	$6.803M	$13.47M
YoY Change	-49.5%	108.63%
Total Long-Term Assets	$166.4M	$192.2M
YoY Change	-13.39%	-10.2%
TOTAL ASSETS
Total Short-Term Assets	$406.6M	$475.5M
Total Long-Term Assets	$166.4M	$192.2M
Total Assets	$573.1M	$667.7M
YoY Change	-14.17%	33.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.966M	$7.627M
YoY Change	30.67%	-19.06%
Accrued Expenses	$41.59M	$46.62M
YoY Change	-10.79%	47.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$22.50M
YoY Change
Total Short-Term Liabilities	$68.09M	$104.1M
YoY Change	-34.58%	84.12%
LONG-TERM LIABILITIES
Long-Term Debt	$207.4M	$197.5M
YoY Change	5.01%	336.95%
Other Long-Term Liabilities	$13.31M	$23.41M
YoY Change	-43.14%	407.08%
Total Long-Term Liabilities	$13.31M	$23.41M
YoY Change	-43.14%	407.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$68.09M	$104.1M
Total Long-Term Liabilities	$13.31M	$23.41M
Total Liabilities	$347.3M	$382.0M
YoY Change	-9.07%	89.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$415.6M	-$311.0M
YoY Change	33.65%	67.46%
Common Stock	$642.9M	$596.6M
YoY Change	7.75%	22.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$225.7M	$285.7M
YoY Change
Total Liabilities & Shareholders Equity	$573.1M	$667.7M
YoY Change	-14.17%	33.32%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	$808.0K	-$40.98M
YoY Change	-101.97%	122.97%
Depreciation, Depletion And Amortization	$5.656M	$4.901M
YoY Change	15.41%	12.72%
Cash From Operating Activities	-$29.16M	-$20.49M
YoY Change	42.28%	39.08%
INVESTING ACTIVITIES
Capital Expenditures	$208.0K	$19.00K
YoY Change	994.74%	-51.28%
Acquisitions
YoY Change
Other Investing Activities	$44.17M	-$7.430M
YoY Change	-694.48%	-41.03%
Cash From Investing Activities	$39.55M	-$11.41M
YoY Change	-446.57%	-45.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$100.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$5.773M	-$1.110M
YoY Change	420.09%	-58.92%
NET CHANGE
Cash From Operating Activities	-$29.16M	-$20.49M
Cash From Investing Activities	$39.55M	-$11.41M
Cash From Financing Activities	-$5.773M	-$1.110M
Net Change In Cash	$4.583M	-$33.04M
YoY Change	-113.87%	-13.69%
FREE CASH FLOW
Cash From Operating Activities	-$29.16M	-$20.49M
Capital Expenditures	$208.0K	$19.00K
Free Cash Flow	-$29.36M	-$20.51M
YoY Change	43.16%	38.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36257
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	RETROPHIN, INC.
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3721 Valley Centre Drive
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41389524	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43153215	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41389524	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43153215	shares
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5309000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	335206000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	290977000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5015000	USD
CY2020Q1	us-gaap	Income Tax Receivable IncomeTaxReceivable	20183000	USD
CY2019Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1395000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	406630000	USD
CY2020Q1	dei	City Area Code CityAreaCode	888
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	969-7879
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	RTRX
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43155572	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67019000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62436000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	289441000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18085000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18048000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	6593000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6082000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	429064000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2617000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2891000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6803000	USD
CY2020Q1	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	8100000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14709000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9966000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	156077000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157200000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	936000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2020Q1	us-gaap	Assets Assets	573063000	USD
CY2019Q4	us-gaap	Assets Assets	604800000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8590000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	636910000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	26614000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41590000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51745000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8435000	USD
CY2019Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	8500000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	68091000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	95449000	USD
CY2020Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	207412000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	204861000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13312000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20894000	USD
CY2020Q1	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	58500000	USD
CY2019Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	62400000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	347315000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	383604000	USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	642880000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-415636000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-416444000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1500000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	726000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	225748000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	573063000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	604800000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47769000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39570000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	1370000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	1017000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30249000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33443000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33139000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32669000	USD
CY2020Q1	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	-1922000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4901000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5656000	USD
CY2019Q1	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3169000	USD
CY2020Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2020Q1	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
CY2019Q1	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	62836000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	77798000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15067000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-38228000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-190000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-302000	USD
CY2020Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1976000	USD
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2819000	USD
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4887000	USD
CY2019Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4865000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3101000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2348000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18168000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40576000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18976000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	401000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	808000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-40977000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43122897	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41410314	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43592499	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41410314	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	808000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-40977000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	191000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	117000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2417000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1469000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1418000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39391000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	808000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	25000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-62000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	61000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-40977000	USD
CY2020Q1	rtrx	Noncash Interest Expense NoncashInterestExpense	517000	USD
CY2019Q1	rtrx	Noncash Interest Expense NoncashInterestExpense	350000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-138000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	343000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25500000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2551000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2459000	USD
CY2020Q1	rtrx	Provision For Inventory ProvisionForInventory	420000	USD
CY2019Q1	rtrx	Provision For Inventory ProvisionForInventory	189000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5910000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6271000	USD
CY2020Q1	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	-1922000	USD
CY2019Q1	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	-14831000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6971000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1405000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-40000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	958000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	170000	USD
CY2020Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	18788000	USD
CY2019Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-304000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-7666000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9625000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-16577000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3103000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-7519000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	9886000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29155000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20492000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	208000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000	USD
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4406000	USD
CY2019Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3961000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	49153000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	72990000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	4988000	USD
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	80422000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39551000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11412000	USD
CY2020Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	5308000	USD
CY2019Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	905000	USD
CY2020Q1	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	525000	USD
CY2019Q1	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	509000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	60000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	304000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5773000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1110000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-40000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-21000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4583000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33035000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67019000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69838000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5714000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6370000	USD
CY2020Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	60000	USD
CY2019Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	304000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2417000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1469000	USD
CY2020Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	191000	USD
CY2019Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	117000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	196000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	175000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	808000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-40977000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	225748000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	285711000	USD
CY2020Q1	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On January 30, 2020, the World Health Organization (“WHO”) declared that the recent novel coronavirus (COVID-19) outbreak was a global health emergency, which prompted national governments to begin putting actions in place to slow the spread of COVID-19. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The outbreak of COVID-19 has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the fiscal quarter ended March 31, 2020, these governmental actions and the widespread economic disruption arising from the pandemic have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Programs:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">,</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (“ARB”). Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#4c4c4c;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Focal segmental glomerulosclerosis ("FSGS")</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#4c4c4c;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Immunoglobulin A nephropathy ("IgAN")</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal® has been recognized as the standard of care for cerebrotendinous xanthomatosis (“CTX”) patients for more than three decades but is not currently labeled for this indication. In January 2020, we randomized the first patients in a Phase 3 clinical trial to evaluate the effects of Chenodal in adult and pediatric patients with CTX. The pivotal study, known as the RESTORE study, is intended to support a new drug application (“NDA”) submission for marketing authorization of Chenodal for CTX in the United States.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Cooperative Research and Development Agreements ("CRADAs"):</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a participant in two CRADAs, which form a multi-stakeholder approach to pool resources with leading experts, and incorporates the patient perspective early in the identification and development process. Retrophi</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">n has partnered with the </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS")</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and leading patients advocacy organizations, NGLY1.org and </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Alagille Syndrome Alliance ("ALGSA")</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome, respectively. There are no treatment options currently approved for these diseases.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Approved products:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for CTX patients for more than three decades.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">® </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div></td></tr></table><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">® </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">and Thiola EC</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">® </span>(tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18100000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	289400000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47769000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39570000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	49200000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	5000000.0	USD
CY2020Q1	us-gaap	Marketable Securities MarketableSecurities	289441000	USD
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	336088000	USD
CY2020Q1	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	203267000	USD
CY2020Q1	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	188000	USD
CY2020Q1	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	607000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	202848000	USD
CY2020Q1	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	87710000	USD
CY2020Q1	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	26000	USD
CY2020Q1	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	1143000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	86593000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	290977000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	214000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1750000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	289441000	USD
CY2019Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	208906000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	598000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	10000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	209494000	USD
CY2019Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	126300000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	351000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	57000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	126594000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	335206000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	949000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	67000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	208257000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1750000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	208257000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1750000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	79151000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	65000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	7509000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	86660000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	67000	USD
CY2020Q1	us-gaap	Cost Method Investments CostMethodInvestments	15000000.0	USD
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000.0	USD
CY2020Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.077
CY2020Q1	rtrx	Lessee Operating Lease Remeasurement Adjustment To Rou Asset And Lease Liability LesseeOperatingLeaseRemeasurementAdjustmentToROUAssetAndLeaseLiability	7000000.0	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1936000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	622000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2558000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	100000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2458000	USD
CY2020Q1	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	1144000	USD
CY2020Q1	rtrx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	1314000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2458000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2458000	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	USD
CY2020Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	195600000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67019000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	289441000	USD
CY2020Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	356460000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	66600000	USD
CY2020Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	66600000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	398524000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	70900000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	70900000	USD
CY2020Q1	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	-1900000	USD
CY2019Q1	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3200000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	156100000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	249783000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	245802000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	93706000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	88602000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	156077000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157200000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5174000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4731000	USD
CY2020Q1	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1300000	shares
CY2020Q1	rtrx	Government Rebates Payable GovernmentRebatesPayable	7945000	USD
CY2019Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	6584000	USD
CY2020Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7830000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	14045000	USD
CY2020Q1	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7199000	USD
CY2019Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7272000	USD
CY2020Q1	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	12481000	USD
CY2019Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16067000	USD
CY2020Q1	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	4363000	USD
CY2019Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3552000	USD
CY2020Q1	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1772000	USD
CY2019Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4225000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41590000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51745000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43122897	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	808000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41410314	shares
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-40977000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2020Q1	rtrx	Dilutive Securities Effecton Basic Earnings Per Share Employee Stock Purchase Plan DilutiveSecuritiesEffectonBasicEarningsPerShareEmployeeStockPurchasePlan	16636	shares
CY2019Q1	rtrx	Dilutive Securities Effecton Basic Earnings Per Share Employee Stock Purchase Plan DilutiveSecuritiesEffectonBasicEarningsPerShareEmployeeStockPurchasePlan	0	shares
CY2020Q1	rtrx	Dilutive Securities Effecton Basic Earnings Per Share Restricted Stock DilutiveSecuritiesEffectonBasicEarningsPerShareRestrictedStock	75044	shares
CY2019Q1	rtrx	Dilutive Securities Effecton Basic Earnings Per Share Restricted Stock DilutiveSecuritiesEffectonBasicEarningsPerShareRestrictedStock	0	shares
CY2020Q1	rtrx	Dilutive Securities Effecton Basic Earnings Per Share Options DilutiveSecuritiesEffectonBasicEarningsPerShareOptions	377922	shares
CY2019Q1	rtrx	Dilutive Securities Effecton Basic Earnings Per Share Options DilutiveSecuritiesEffectonBasicEarningsPerShareOptions	0	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43592499	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	808000	USD
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41410314	shares
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-40977000	USD
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14807564000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16614304000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5200000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.11
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5910000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6520000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19000000.0	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3085000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2713000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3508000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3369000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	6593000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6082000	USD
CY2020Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3200000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3100000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18100000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18000000.0	USD
CY2016Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	500000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25000000.0	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2300000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5700000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1000000.0	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2019Q1	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000.0	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7500000	USD
CY2020Q1	rtrx	At The Market Equity Offering Program Maximum Amount Authorized AtTheMarketEquityOfferingProgramMaximumAmountAuthorized	100000000.0	USD
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares

Files In Submission

Name	View Source	Status
0001438533-20-000011-index-headers.html	Edgar Link	pending
0001438533-20-000011-index.html	Edgar Link	pending
0001438533-20-000011.txt	Edgar Link	pending
0001438533-20-000011-xbrl.zip	Edgar Link	pending
ex03312020101.htm	Edgar Link	pending
ex03312020102.htm	Edgar Link	pending
ex03312020103.htm	Edgar Link	pending
ex03312020311.htm	Edgar Link	pending
ex03312020312.htm	Edgar Link	pending
ex03312020321.htm	Edgar Link	pending
ex03312020322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
productpipelineq319a02.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20200331.xsd	Edgar Link	pending
rtrx-20200331x10q.htm	Edgar Link	pending
rtrx-20200331x10q_htm.xml	Edgar Link	completed
rtrx-20200331_cal.xml	Edgar Link	unprocessable
rtrx-20200331_def.xml	Edgar Link	unprocessable
rtrx-20200331_lab.xml	Edgar Link	unprocessable
rtrx-20200331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2020 Q1 Form 10-Q Financial Statement

#000143853320000011 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2020 Q1 Form 10-Q Financial Statement

#000143853320000011 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx